Summit Therapeutics Inc. (SMMT) is listed on NASDAQ in Pharmaceutical Stocks. It is $13.71, -4.33%, with a $10.9B market cap. RSI is 51.0, neutral. The latest reported quarter met estimates. Insiders were net buyers across the listed trades.
Technical Analysis
RSI (14) 51.0 Neutral
Market Cap $10.9B
Volume 3.0M
Fundamentals — 10-Q Q2 2026
Revenue --
Net Income $-405.1M
EPS $-0.52
P/E Ratio -26.4x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | 2026 Jun 12 |
| Duggan Robert W | Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | 2026 Jun 12 |
| Duggan Robert W | Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | 2026 Jun 4 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | 2026 Jun 4 |
| Soni Manmeet Singh | COO and CFO | Buy | 50,000 | $14.45 | $722,250 | 2026 Jun 4 |
| Xia Yu | Director | Buy | 533,617 | $18.74 | $10.0M | 2025 Oct 21 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 26,680 | $18.74 | $499,983 | 2025 Oct 21 |
| Duggan Robert W | Co-Chief Executive Officer | Buy | 26,680 | $18.74 | $499,983 | 2025 Oct 21 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 338,394 | $17.69 | $6.0M | 2025 Sep 11 |
| Duggan Robert W | Co-Chief Executive Officer | Buy | 338,394 | $17.69 | $6.0M | 2025 Sep 11 |
| Zanganeh Mahkam | Chief Executive Officer | Buy | 110,321 | $3.73 | $411,094 | 2024 Mar 27 |
| Dhingra Ankur | Chief Financial Officer | Buy | 100,000 | $3.75 | $375,000 | 2024 Mar 26 |
| Dhingra Ankur | Chief Financial Officer | Buy | 20,400 | $2.17 | $44,254 | 2023 Dec 13 |
| Zanganeh Mahkam | Chief Executive Officer | Buy | 5,000 | $2.07 | $10,350 | 2023 Dec 12 |
| Soni Manmeet Singh | Chief Operating Officer | Buy | 2,976,190 | $1.68 | $5.0M | 2023 Oct 13 |
| Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 23,527,044 | $1.05 | $24.7M | 2023 Mar 8 |
| Dhingra Ankur | Chief Financial Officer | Buy | 196,362 | $1.05 | $206,180 | 2023 Mar 7 |
| Duggan Robert W | Chief Executive Officer | Buy | 376,489,880 | $1.05 | $395.3M | 2023 Mar 6 |
| Zanganeh Maky | Co-CEO & President | Buy | 5,809,132 | $0.97 | $5.6M | 2022 Aug 16 |
| Duggan Robert W | Chief Executive Officer | Buy | 94,849,203 | $0.97 | $92.0M | 2022 Aug 16 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $53.91 | 53.0 | $8.3B |
| | $34.78 | 68.0 | $3.9B |
| | $105.79 | 46.8 | $5.9B |
| | $32.15 | 38.6 | $3.8B |
| | $33.21 | 63.0 | -- |
Take SMMT further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put SMMT in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Summit Therapeutics Inc. next reports.
Set alerts on SMMT
Get notified when Summit Therapeutics Inc. hits your price targets or technical conditions are met.
Get Started Free